

## Primary Driver In The Eczema Market 2025: Increasing Prevalence Of Autoimmune Disorders Driving Growth In The Market

The Business Research Company's Eczema Global Market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034

LONDON, GREATER LONDON, UNITED KINGDOM, March 25, 2025 /EINPresswire.com/ -- Updated 2025 Market Reports Released: Trends,



Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

The anticipated growth in the worldwide <u>eczema market</u>, from \$16.41 billion in 2024 to \$17.81 billion in 2025 at a compound annual growth rate CAGR of 8.5%, unveils a promising landscape for stakeholders and investors. Longer-term projections estimate the market size to appreciate to even greater heights, reaching \$24.35 billion in 2029 at a CAGR of 8.1%. Driving this upward trajectory is the rising prevalence of autoimmune diseases, increased eczema cases, approvals from authorities, and the prevalence of air pollutants and allergic reactions.

What is propelling the eczema market's substantial growth?

A key growth driver anticipated to shape the eczema market is the increasing prevalence of autoimmune disorders, defined as conditions in which the body's immune system attacks its healthy cells, tissues, or organs causing inflammation and damage. The escalating rate of autoimmune disorders is linked to factors such as genetic susceptibility, environmental factors, infections, dietary changes, and stress. An example is the Germany-based organization, Versorgungsatlas.de, which reported that, in 2022, out of 73,241,305 insured individuals, 6,304,340 were diagnosed with at least one autoimmune disease – a raw prevalence rate of 8.61%.

Get Your Free Sample Market Report:

https://www.thebusinessresearchcompany.com/sample\_request?id=21179&type=smp

Who are the key industry players fueling the progress of the eczema market? Prominent companies operating in the eczema market include Pfizer Inc., AbbieVie Inc., Bayer

AG, Sanofi S.A, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Amgen, Hoffmann-La Roche AG, Eli Lilly and Co., Siemens Healthineers AG, Viatris Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc, Bausch Health Companies Inc., Galderma, Cadila Pharmaceuticals Ltd., LEO Pharma A/S, Almirall, Kyowa Kirin, Alliance Pharma Plc, Encore Dermatology Inc., and Arcutis Inc.

Are there any industry trends we should keep our eyes on?

One of the prominent trends in the eczema market is the focus of companies on the development of innovative products, such as eczema care creams. Such development aims to enhance treatment effectiveness and meet the demand for advanced skincare solutions. In September 2024, Dove, a UK-based personal care brand, launched a new Eczema Care range for babies. The newly introduced products are formulated with 100% skin-natural nutrients, making them gentle on sensitive skin and contain colloidal oatmeal 1.0%, a key ingredient for soothing irritation and maintaining moisture.

How is the <u>eczema market segmented</u>?

The market encompasses various segments such as -

By Type: Atopic Dermatitis, Contact Dermatitis, Seborrheic Dermatitis, Other Types

By Treatment Type: Topical Treatments, Oral Medications, Biologics, Phototherapy

By Age Group: Children, Adults, Elderly

By End User: Hospitals Or Clinics, Dermatology Centers, Home Care, Pharmacies

Additionally, there are sub-segments within these primary segments, like Atopic Dermatitis that further includes Topical Steroids, Topical Calcineurin Inhibitors, Moisturizers, Biologic Therapies, and many more.

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/eczema-global-market-report

What are the market's regional insights?

North America was the largest region in the eczema market in 2024. The report also converges on other regions like Asia-Pacific, Western Europe, Eastern Europe, South America, the Middle East, and Africa.

In conclusion, even with a conservative outlook, the global eczema market offers a panorama of opportunities for investors and market stakeholders. The forecasted growth in market size, coupled with the greater emphasis on autoimmune disorders, builds an undeniable case for investing in this evolving sector.

Browse For More Similar Reports-

Atopic Dermatitis Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/atopic-dermatitis-global-market-report

Dermatitis Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/dermatitis-drugs-global-market-report

Atopic Dermatitis Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/atopic-dermatitis-global-market-report

<u>The Business Research Company</u> invites you to browse through more similar reports. With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

## Contact us at:

The Business Research Company: <a href="https://www.thebusinessresearchcompany.com/">https://www.thebusinessresearchcompany.com/</a>

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

## Follow us on:

LinkedIn: <a href="https://in.linkedin.com/company/the-business-research-company/">https://in.linkedin.com/company/the-business-research-company/</a> YouTube: <a href="https://www.youtube.com/channel/UC24\_fl0rV8cR5DxlCpgmyFQ">https://www.youtube.com/channel/UC24\_fl0rV8cR5DxlCpgmyFQ</a>

Global Market Model: <a href="https://www.thebusinessresearchcompany.com/global-market-model">https://www.thebusinessresearchcompany.com/global-market-model</a>

Oliver Guirdham

The Business Research Company

+44 20 7193 0708

info@tbrc.info

Visit us on social media:

Facebook

Χ

LinkedIn

This press release can be viewed online at: https://www.einpresswire.com/article/796892688

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.